adenine has been researched along with Idiopathic Parkinson Disease in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Congenital hydrocephalus (CH) is caused by genetic mutations, but whether factors impacting human genetic mutations are disease-specific remains elusive." | 2.72 | Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions. ( Hart, C; McKnight, I; Park, IH; Shim, JW, 2021) |
| "At the molecular level, Parkinson's disease share common molecular signatures with most neurodegenerative diseases including the accumulation of misfolded proteins in the brain." | 2.61 | Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease. ( Gonzalez, C; Hetz, C; Lopez, N; Martinez, A, 2019) |
| "Neurodegenerative diseases are characterized by the aggregation of misfolded proteins in the brain." | 2.50 | Prions: generation and spread versus neurotoxicity. ( Halliday, M; Mallucci, GR; Radford, H, 2014) |
| "Baicalein was administrated from 7 to 12 week." | 1.46 | Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy. ( Cao, X; Kuang, L; Lu, Z, 2017) |
| "L-Dopa, the standard therapeutic for Parkinson's disease, is inactivated by the enzyme catechol-O-methyltransferase (COMT)." | 1.37 | Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. ( Borroni, E; Diederich, F; Ehler, A; Ellermann, M; Jakob-Roetne, R; Lerner, C; Paulini, R; Roth, D; Rudolph, MG; Schlatter, D; Schweizer, WB, 2011) |
| "Monogenic forms of Parkinson's disease (PD) provide an opportunity to examine mechanisms underlying phenotypic variation." | 1.34 | Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease. ( Athanassiadou, A; Bonifati, V; Di Iorio, G; Golbe, LI; Johnson, WG; Markopoulou, K; Papapetropoulos, S; Spychala, JR; Stenroos, ES; Vance, JM; Watts, RL; Williams, TA, 2007) |
| "All compounds tested reversed the catalepsy induced by haloperidol." | 1.33 | New adenosine A2A receptor antagonists: actions on Parkinson's disease models. ( Cristalli, G; Morelli, M; Pinna, A; Volpini, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Pupyshev, AB | 1 |
| Tenditnik, MV | 1 |
| Ovsyukova, MV | 1 |
| Akopyan, AA | 1 |
| Dubrovina, NI | 1 |
| Tikhonova, MA | 1 |
| McKnight, I | 1 |
| Hart, C | 1 |
| Park, IH | 1 |
| Shim, JW | 1 |
| Kuang, L | 1 |
| Cao, X | 1 |
| Lu, Z | 1 |
| Martinez, A | 1 |
| Lopez, N | 1 |
| Gonzalez, C | 1 |
| Hetz, C | 1 |
| Yang, F | 1 |
| Yang, YP | 1 |
| Mao, CJ | 1 |
| Liu, L | 1 |
| Zheng, HF | 1 |
| Hu, LF | 1 |
| Liu, CF | 1 |
| Piersanti, G | 1 |
| Bartoccini, F | 1 |
| Lucarini, S | 1 |
| Cabri, W | 1 |
| Stasi, MA | 1 |
| Riccioni, T | 1 |
| Borsini, F | 2 |
| Tarzia, G | 1 |
| Minetti, P | 1 |
| Endo, K | 1 |
| Deguchi, K | 1 |
| Matsunaga, H | 1 |
| Tomaya, K | 1 |
| Yamada, K | 1 |
| Halliday, M | 1 |
| Radford, H | 1 |
| Mallucci, GR | 1 |
| Yakhine-Diop, SM | 1 |
| Bravo-San Pedro, JM | 1 |
| Gómez-Sánchez, R | 1 |
| Pizarro-Estrella, E | 1 |
| Rodríguez-Arribas, M | 1 |
| Climent, V | 1 |
| Aiastui, A | 1 |
| López de Munain, A | 1 |
| Fuentes, JM | 1 |
| González-Polo, RA | 1 |
| Zhang, Y | 1 |
| Wu, JY | 1 |
| Weng, LH | 1 |
| Li, XX | 1 |
| Yu, LJ | 1 |
| Xu, Y | 1 |
| Volpini, R | 4 |
| Dal Ben, D | 1 |
| Lambertucci, C | 1 |
| Marucci, G | 2 |
| Mishra, RC | 1 |
| Ramadori, AT | 1 |
| Klotz, KN | 1 |
| Trincavelli, ML | 1 |
| Martini, C | 1 |
| Cristalli, G | 4 |
| Finaurini, S | 1 |
| Buccioni, M | 1 |
| Lammi, C | 1 |
| Kandhavelu, M | 1 |
| Ricciutelli, M | 1 |
| Angeli, P | 1 |
| Commandeur, JN | 1 |
| Pinna, A | 4 |
| Tronci, E | 1 |
| Schintu, N | 1 |
| Simola, N | 1 |
| Pontis, S | 2 |
| Morelli, M | 3 |
| Oses, JP | 1 |
| Batassini, C | 1 |
| Pochmann, D | 1 |
| Böhmer, AE | 1 |
| Vuaden, FC | 1 |
| Silvestrin, RB | 1 |
| Oliveira, A | 1 |
| Bonan, CD | 1 |
| Bogo, MR | 1 |
| Souza, DO | 1 |
| Portela, LV | 1 |
| Sarkis, JJ | 1 |
| Mello e Souza, T | 1 |
| Hassin-Baer, S | 1 |
| Hattori, N | 1 |
| Cohen, OS | 1 |
| Massarwa, M | 1 |
| Israeli-Korn, SD | 1 |
| Inzelberg, R | 1 |
| Ellermann, M | 1 |
| Paulini, R | 1 |
| Jakob-Roetne, R | 1 |
| Lerner, C | 1 |
| Borroni, E | 1 |
| Roth, D | 1 |
| Ehler, A | 1 |
| Schweizer, WB | 1 |
| Schlatter, D | 1 |
| Rudolph, MG | 1 |
| Diederich, F | 1 |
| Jiang, TF | 1 |
| Zhang, YJ | 1 |
| Zhou, HY | 1 |
| Wang, HM | 1 |
| Tian, LP | 1 |
| Liu, J | 1 |
| Ding, JQ | 1 |
| Chen, SD | 1 |
| GOMIRATO, G | 1 |
| HYDEN, H | 1 |
| Golbe, LI | 1 |
| Di Iorio, G | 1 |
| Markopoulou, K | 1 |
| Athanassiadou, A | 1 |
| Papapetropoulos, S | 1 |
| Watts, RL | 1 |
| Vance, JM | 1 |
| Bonifati, V | 1 |
| Williams, TA | 1 |
| Spychala, JR | 1 |
| Stenroos, ES | 1 |
| Johnson, WG | 1 |
| Vilar, R | 1 |
| Coelho, H | 1 |
| Rodrigues, E | 1 |
| Gama, MJ | 1 |
| Rivera, I | 1 |
| Taioli, E | 1 |
| Lechner, MC | 1 |
| Lücking, CB | 1 |
| Kösel, S | 1 |
| Mehraein, P | 1 |
| Graeber, MB | 1 |
| Loeffler, DA | 1 |
| Camp, DM | 1 |
| Juneau, PL | 1 |
| Harel, E | 1 |
| LeWitt, PA | 1 |
| Barbieri, S | 1 |
| Hofele, K | 1 |
| Wiederhold, KH | 1 |
| Probst, A | 1 |
| Mistl, C | 1 |
| Danner, S | 1 |
| Kauffmann, S | 1 |
| Sommer, B | 1 |
| Spooren, W | 1 |
| Tolnay, M | 1 |
| Bilbe, G | 1 |
| van der Putten, H | 1 |
5 reviews available for adenine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions.
Topics: Adenine; Alzheimer Disease; Animals; Carrier Proteins; Chromosome Mapping; Chromosomes; Databases, G | 2021 |
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease.
Topics: Adenine; Adrenergic alpha-2 Receptor Agonists; Animals; Disease Models, Animal; Endoplasmic Reticulu | 2019 |
Prions: generation and spread versus neurotoxicity.
Topics: Adenine; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; eIF-2 Kinase; Humans; I | 2014 |
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials, Phase I | 2009 |
Mouse models of alpha-synucleinopathy and Lewy pathology. Alpha-synuclein expression in transgenic mice.
Topics: Adenine; alpha-Synuclein; Alzheimer Disease; Animals; Brain; Disease Models, Animal; Humans; Lewy Bo | 2001 |
21 other studies available for adenine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Restoration of Parkinson's Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson's Disease in Mice.
Topics: Adenine; Animals; Autophagy; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Transgenic; MTO | 2021 |
Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy.
Topics: Adenine; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dop | 2017 |
Crosstalk between the proteasome system and autophagy in the clearance of α-synuclein.
Topics: Adenine; alpha-Synuclein; Animals; Autophagy; Cell Survival; Chymotrypsin; Humans; Oligopeptides; Pa | 2013 |
Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Binding, Competitive; CHO Cel | 2013 |
8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Antipsychotic Agents; Cat | 2014 |
G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
Topics: 1-Methyl-4-phenylpyridinium; Adenine; Autophagy; Case-Control Studies; Caspases; Cells, Cultured; Do | 2014 |
Valproic acid protects against MPP
Topics: 1-Methyl-4-phenylpyridinium; Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Humans; | 2017 |
Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Binding Sites; Computer Simulation; Crystallogr | 2009 |
In vitro metabolism studies of new adenosine A 2A receptor antagonists.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Chromatography, High Pressure Liquid; Cytochrom | 2008 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiograph | 2010 |
The hydrolysis of striatal adenine- and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 5'-Nucleotidase; Acid Anhydride Hydrolases; Adenine; Adrenergic Agents; Animals; Corpus Striatum; Di | 2011 |
Phenotype of the 202 adenine deletion in the parkin gene: 40 years of follow-up.
Topics: Adenine; Adult; Age of Onset; Aged; Disability Evaluation; Disease Progression; Family Health; Femal | 2011 |
Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.
Topics: Adenine; Catalysis; Catalytic Domain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inh | 2011 |
Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.
Topics: Adenine; alpha-Synuclein; Autophagy; Blotting, Western; Cell Line; Cell Survival; Curcumin; Genetic | 2013 |
A BIOCHEMICAL GLIA ERROR IN THE PARKINSON DISEASE.
Topics: Adenine; Cytosine; Globus Pallidus; Guanine; Neurochemistry; Neuroglia; Neurons; Nucleic Acids; Park | 1963 |
New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Anim | 2005 |
Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease.
Topics: Adenine; Adult; Age of Onset; Aged; Aged, 80 and over; Alleles; alpha-Synuclein; Glutathione Transfe | 2007 |
Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease.
Topics: Adenine; Aged; Aged, 80 and over; Alleles; Cytochrome P-450 CYP2D6; Gene Deletion; Genetic Predispos | 2007 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functi | 2007 |
Absence of the mitochondrial A7237T mutation in Parkinson's disease.
Topics: Adenine; Base Sequence; DNA Primers; DNA, Mitochondrial; Electron Transport Complex IV; Frontal Lobe | 1995 |
Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells.
Topics: Adenine; Adenosine; Animals; Disease Models, Animal; Dopamine; Guanine; Guanosine; Hypoxanthine; Neo | 2000 |